Feb 12, 2015 · There was no significant difference in the risk of death from any cause between tiotropium Respimat 5 micrograms or 2
5 μg versus HandiHaler, the Treatment exposure to Spiriva HandiHaler was 10,927 patient-years
Spiriva (tiotropium) is a medication used to help control chronic obstructive pulmonary disease (COPD) and asthma
There are two different Spiriva inhalers: Spiriva Respimat is a metered-dose inhaler, and Spiriva HandiHaler is a device that you place a capsule of medication into
In the studies, a measurement called FEV1 was
For the primary end point of the risk of death from any cause, the hazard ratio for Respimat 5 μg versus HandiHaler was 0
In a survey, 80% preferred SPIRIVA RESPIMAT to SPIRIVA® HANDIHALER® (tiotropium bromide inhalation powder) after a 2-to-3-year follow-up
A Spiriva capsule is for use only in the HandiHaler device
Compare Spiriva head-to-head with other drugs for uses, ratings, cost, side effects and interactions
SPIRIVA RESPIMAT, 1
Newman S
Spiriva Respimat Inhaler vs
Use only one capsule at a time
Spiriva HandiHaler powder is packaged in capsules that are for use only with a special inhaler device (Spiriva HandiHaler)
Spiriva comes in 2 forms: Spiriva Respimat® (tiotropium bromide inhalation spray) Spiriva HandiHaler® (tiotropium bromide inhalation powder) The active ingredient in Spiriva Respimat and Spiriva HandiHaler is tiotropium
Dose selection for the Phase III clinical program was supported by a 3-week randomized, double-blind, placebo and active-controlled, parallel group trial in 202 COPD patients
38% of reviewers reported a positive effect, while 38% reported a negative effect
Save up to $401 on 1 inhaler (30 capsules) of tiotropium 18mcg per capsule with GoodRx today
In the treatment of asthma, the maximum benefits in lung function may take up to 4 to 8 weeks of dosing [see Patient Counseling Information (17)]
94 to –3
We aimed to compare available bronchodilator efficacy data of once-daily Respimat 1
49 for the most common version, by using a GoodRx coupon
Following 4-week SPIRIVA HANDIHALER or SPIRIVA RESPIMAT once daily dosing in patients with COPD, mild renal impairment p = 0
9 hours
All-cause mortality was similar between SPIRIVA HANDIHALER and
com